Navin Fluorine International Ltd

The transcript provided does not mention any current or future plans for fundraising through debt or equity by Navin Fluorine International Limited. Key points related to financial health and capital allocation include: - The company reported a negligible net debt-to-equity ratio of 0.01x as of March 31, 2026, indicating a strong balance sheet. - Management emphasizes maintaining a strong balance sheet and capital allocation focus to deliver long-term shareholder value. - The company is transitioning projects like the Chemours project and additional HFC capacities from investment phase to revenue generation in the current year. - No explicit statements or plans to raise new debt or equity financing were disclosed during the call. Hence, based on the available information, there are no announced plans for new debt or equity fundraising at this time.

- Chemours project is on track for commissioning by end of June/early July 2026. - Post commissioning, an 18-month period will help understand market size, guiding future capex decisions linked to Chemours. - The company plans capacity expansions like cGMP5 and beyond (up to blocks 5, 6, and 7) if volume visibility and business case materialize. - New capacities include the commissioned HF plant and upcoming R32 plant, expected to drive growth from FY28 onwards. - Debottlenecking and new capex plans related to specialty chemicals and refrigerant gases are in the pipeline with stated timelines. - No new acquisitions or technology capabilities have been added recently; capacity expansions are organic and scalable. - The company emphasizes capacity utilization increase (e.g., Nectar project aiming for 75%-80% utilization by FY28).

Future growth expectations for Navin Fluorine International Limited: - **HPP Business**: - R32 and HFC capacities expansion (15,000 MT/year) commissioning expected by Q3 FY27. - AHF plant commercial supplies commenced; further growth expected from new capacities. - Shift towards India in sales; new geographies and customers being targeted. - Demand-supply environment remains constructive with increasing adoption of low GWP refrigerants. - **Specialty Chemicals**: - Q4 FY26 revenue up 39% YoY; ongoing scale-up in existing and new molecules. - Dahej MPP debottlenecking capex on track for Q3 FY27. - Chemours project to be completed by July FY27. - Order visibility and robust pipeline support sustained growth. - Target of 75%-80% capacity utilization for Nectar plant by end FY28. - **CDMO**: - 61% revenue growth YoY in Q4 FY26. - Balanced mix of early-, late-stage, and commercial molecules. - Continued double-digit revenue growth expected in FY27. - **Overall revenue growth**: - Specialty chemicals and HPP segments expected to maintain high double-digit growth. - General volume growth in range of 7.5%-9% modeled for other segments.

- FY26 financials showed strong growth: consolidated revenue up 41%, EBITDA doubled, and PAT up 130%+. - Operating EBITDA margin expanded significantly to 32.6% in FY26. - Management targets margin guidance of around 30% for FY27, with a ±1-2% tolerance. - Growth drivers for FY27 include ramp-up of the newly commissioned HF plant, Nectar fluorochemical plant (expected 75-80% utilization by FY28), Dahej MPP debottlenecking, and new R32 HFC capacity expansion (commissioning in Q3 FY27). - The CDMO and Specialty Chemicals segments to sustain high double-digit growth driven by new molecule introductions and strong order visibility. - Continued operational efficiencies expected to improve return ratios. - Agchem export-driven demand remains robust with no current disruption. - Overall cautious growth estimate for FY27 revenue growth is in the 7.5% to 9% range, with emphasis on sustainable profitability.

- For FY28 in the agro specialty segment, order visibility indicates a capacity utilization target of around 80%, considered optimal for an MPP environment. - The company processed 13 new molecules in the specialty business in FY26, with three introduced in Q4. - Contracted volumes for the Nectar project are fully covered; additional molecules offer better risk management with ongoing qualification shipments and downstream applications being explored. - Current utilization for Nectar plant expected around 75%-80% by end of FY28. - No visible demand disruption; order books and order visibility remain solid. - CDMO business sees strong growth with expanded capabilities and a mix of early and late-stage molecules. - Contract liabilities increased to approximately INR 211 crores, driven by ongoing contracts and order dynamics.